Sunshine BiopharmavsUnitedHealth

SBFM and UNH stock compared: price, dividend, valuation and results, from SEC filings.

SBFM

Sunshine Biopharma Inc.

$2.41

Value $2.0M

-5.12%
SBFM's page

UNH

UnitedHealth Group Incorporated

$349.91

Value $318B

-10.21%
UNH's page

Sunshine Biopharma (SBFM) has a market value of $2.0M and UnitedHealth (UNH) $318B. Over the last year, with dividends, SBFM moved -99.2% and UNH +12.1%. Dividend yield: SBFM none, UNH 2.59%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    SBFM$2.0M

    UNH$318B

    UNH is 159,979 times SBFM

  • Revenue, 12 months

    SBFM$35M

    UNH$450B

    UNH is 12,712 times SBFM

  • Net income, 12 months

    SBFM-$6.2M

    UNH$15.9B

  • Operating margin

    SBFM-17.2%

    UNH5.3%

    22.5 points apart

  • ROIC

    SBFM-19.3%

    UNH11.3%

    30.5 points apart

  • P/E

    SBFM–

    UNH20.0

  • Dividend yield

    SBFM0.0%

    UNH2.6%

    2.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

SBFM-100.0%

UNH-30.5%

050100202420252026
Returns by period
PeriodSBFMWith dividendsUNHWith dividends
1 year since November 17, 2025-99.2%Price -99.2%+12.1%Price +9.2%
3 years since November 17, 2023-100.0%-97.2% a yearPrice -100.0%-30.5%-11.4% a yearPrice -34.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

SBFMSunshine BiopharmaUNHUnitedHealth

Valuation

SBFMUNH
Valuation
Price$2.41$349.91
Market value$2.0M$318B
Enterprise value (EV)–$363B
P/E–20.0
P/E, 5-year median–25.0
P/B0.13.1
EV/EBIT–15.2
Free cash flow yield–7.2%

Results and growth

SBFMUNH
Results and growth
Revenue, 12 months$35M$450B
Net income, 12 months-$6.2M$15.9B
Free cash flow, 12 months-$6.0M$22.8B
Earnings per share, 12 months-$170.83$17.52
Revenue growth, year on year4.1%11.8%
Revenue growth a year, past+247.7%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

SBFMUNH
Margins and returns on capital
Gross margin30.4%88.3%
Operating margin-17.2%5.3%
Net margin-17.5%3.5%
ROIC-19.3%11.3%
ROE-24.7%15.5%

Balance sheet

SBFMUNH
Balance sheet
Cash$15M$28.5B
Total debt$627.6K$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

SBFMUNH
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.8%
Shareholder yield–4.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: SBFM or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Sunshine Biopharma or UnitedHealth?

By market value, UnitedHealth ($318B) is about 159,979.0 times Sunshine Biopharma ($2.0M), at today's prices.

How did SBFM and UNH stock do over the last 3 years?

Since November 17, 2023, SBFM's price moved -100.0% and UNH's -34.8%. With dividends: SBFM -100.0% (-97.2% a year), UNH -30.5% (-11.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, SBFM or UNH?

The dividend yield at today's price is none for Sunshine Biopharma and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Sunshine Biopharma or UnitedHealth?

Over the last twelve months, the net margin was -17.5% for Sunshine Biopharma and 3.5% for UnitedHealth, and the operating margin -17.2% and 5.3%. Revenue was $35M and $450B.

Which is the better investment, Sunshine Biopharma or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.